224 related articles for article (PubMed ID: 23518148)
21. CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria.
Meyer M; Hohenberger P; Apfaltrer P; Henzler T; Dinter DJ; Schoenberg SO; Fink C
Eur J Radiol; 2013 Jun; 82(6):923-8. PubMed ID: 23410905
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
23. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
[TBL] [Abstract][Full Text] [Related]
24. Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response?
Apfaltrer P; Meyer M; Meier C; Henzler T; Barraza JM; Dinter DJ; Hohenberger P; Schoepf UJ; Schoenberg SO; Fink C
Invest Radiol; 2012 Jan; 47(1):65-70. PubMed ID: 21934517
[TBL] [Abstract][Full Text] [Related]
25. [Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Kanazawa A; Tsukamoto T; Ikehara T; Nishiguchi Y
Gan To Kagaku Ryoho; 2014 Jan; 41(1):55-8. PubMed ID: 24423952
[TBL] [Abstract][Full Text] [Related]
26. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
27. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
28. Liver volume variations as a parameter to assess therapy response in advanced metastatic liver disease.
Kalkmann J; Forsting M; Stattaus J
Onkologie; 2011; 34(1-2):30-4. PubMed ID: 21346382
[TBL] [Abstract][Full Text] [Related]
29. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
[No Abstract] [Full Text] [Related]
30. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
[TBL] [Abstract][Full Text] [Related]
31. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
32. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
33. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
34. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
Kyriazoglou A; Jespers P; Vandecavaye V; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Zaffaroni F; Litière S; Nzokirantevye A; Schöffski P
Acta Oncol; 2022 Jun; 61(6):663-668. PubMed ID: 35481400
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
[TBL] [Abstract][Full Text] [Related]
36. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
[TBL] [Abstract][Full Text] [Related]
37. Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy.
Schlemmer M; Sourbron SP; Schinwald N; Nikolaou K; Becker CR; Reiser MF; Berger F
Eur J Radiol; 2011 Feb; 77(2):312-8. PubMed ID: 19720488
[TBL] [Abstract][Full Text] [Related]
38. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
Klingenstein A; Haug AR; Zech CJ; Schaller UC
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
[TBL] [Abstract][Full Text] [Related]
39. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
40. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]